Targeted delivery of short interfering RNAs - Strategies for in vivo delivery

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 1, 2009, Pages 1-8

  Wullner, Ulrich ^a   Neef, Inga ^a   Tur, Mehmet K ^b   Barth, Stefan ^a,b  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Cell specific ligands; Non targeted delivery; RNA interference; Specific knock down; Targeted delivery

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN B; APTAMER; ARGINYLGLYCYLASPARTIC ACID; ASIALOGLYCOPROTEIN RECEPTOR; CELL PENETRATING PEPTIDE; CHOLINERGIC RECEPTOR; CYCLODEXTRIN; DOUBLE STRANDED RNA; GREEN FLUORESCENT PROTEIN; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LENTIVIRUS VECTOR; LIPOPLEX; LIPOSOME; MACROGOL; MICRORNA; NANOPARTICLE; POLYETHYLENEIMINE; POLYLYSINE; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; STREPTAVIDIN; TRANSFERRIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; CANCER GENE THERAPY; CELL MEMBRANE TRANSPORT; DRUG ADMINISTRATION ROUTE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; ENCAPSULATION; EWING SARCOMA; EYE DISEASE; GENE EXPRESSION; GENE TARGETING; HEPATITIS B; HUMAN; IN VIVO GENE TRANSFER; ISOTOPE LABELING; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; RADIOACTIVITY; REVIEW; RNA BINDING; RNA INTERFERENCE; RNA SEQUENCE; SUBRETINAL DRUG ADMINISTRATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; TISSUE DISTRIBUTION;

ANIMALS; APTAMERS, NUCLEOTIDE; DRUG DELIVERY SYSTEMS; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 62749120320     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209787002506     Document Type: Review

References (96)

1. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806-811.
2. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411(6836): 494-498.
3. Dorsett Y, Tuschl T. siRNAs: Applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004; 3(4): 318-329.
4. Check E. A crucial test. Nat Med 2005; 11(3): 243-244.
5. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77(3): 225-231.
6. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11(3): 263-270.
7. Vargeese, C., Jadhav, V., Morrissey, D.: US2006217332A1 (2006).
8. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452(7187): 591-597.
9. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008; 132(1): 9-14.
10. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409(6818): 363-366.
11. Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001; 293(5531): 834-848.
12. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101(1): 25-33.
13. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23(2): 222-226.
14. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110(5): 563-574
15. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004; 305(5689): 1434-1437.
16. Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004; 305(5689): 1437-1441.
17. Rand TA, Petersen S, Du F, Wang X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 2005; 123(4): 621-629.
18. Martinez J, Tuschl T. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev 2004; 18(9): 975-980.
19. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20(23): 6877-6888.
20. Paroo Z, Corey DR. Challenges for RNAi in vivo. Trends Biotechnol 2004; 22(8): 390-394.
21. Chiu YL, Rana TM. siRNA function in RNAi: A chemical modification analysis. RNA 2003; 9(9): 1034-1048.
22. Vornlocher, H., Hadwiger, P., Zimmermann, T., Manoharan, M., Rajeev, K. G., Roehl, I., Akinc, A.: WO2005115481A2 (2005).
23. Leake, D., Reynolds, A., Khvorova, A., Marshall, W., Federov, Y., Nichols, K.: WO2004090105A2 (2004).
24. Braasch DA, Paroo Z, Constantinescu A, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004; 14(5):1139-1143.
25. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006; 13(16): 1222-1234.
26. Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004; 32(13): e109, doi:10.1093/nar/gnh093.
27. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23(8): 1002-1007.
28. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441(7089): 111-114.
29. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432(7014): 173-178.
30. Dong, X.: US20030166512 (2003).
31. Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9(4): 493-501.
32. Song E, Lee SK, Dykxhoorn DM, et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003; 77(13): 7174-7181.
33. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11(1): 50-55.
34. Brito, L., Chen, D., Qin, G., Doug, T.: US2007172430A1 (2007).
35. Thakker DR, Natt F, Husken D, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 2004; 101(49): 17270-17275.
36. Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: From biophysics to biological applications. Adv Drug Deliv Rev 2001; 47(2-3): 277-294.
37. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 2004; 24(1): 132-138.
38. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-216.
39. Vigna E, Naldini L. Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2(5): 308-316.
40. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20(10): 1006-1010.
41. Singer O, Marr RA, Rockenstein E, et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005; 8(10): 1343-1349.
42. Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10(8): 816-820.
43. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348(3): 255-256.
44. Sinn PL, Sauter SL, McCray PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther 2005; 12(14): 1089-1098.
45. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6(7): 1258-1266.
46. Zhang G, Gao X, Song YK, et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004; 11(8): 675-682.
47. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002; 418(6893): 38-39.
48. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004; 14(19): 4975-4977.
49. Ahmadian, M., Cui, K., Chen, L., Chen, S. S., Houston, M. E.: WO2006019430A2 (2006).
50. Kim, S. H, Jeong, J. H., Park, T. G.: WO2007021142A1 (2007).
51. Hallbrink M, Floren A, Elmquist A, et al. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 2001; 1515(2):101-109.
52. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004; 558(1-3):63-68.
53. Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 2007; 21(11): 2664-2671.
54. Alluis, B., Fruchardt, J. S.: WO2007069068A2 (2007).
55. Cui, K., Chen, L., Chen, Y.: WO2006037126A2 (2006).
56. Dowdy, S. F., Wadia, J. S., Meade, B., Eguchi, A.: WO2007095152A2 ( 2007).
57. Sweedler, D. S.: US2007213257A1 (2007).
58. Troy, C. M., Greene, L. A.: US2006178297A1 (2006).
59. Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007; 18(5): 1450-1459.
60. Maclachlan, I., Ambegia, E. G., James, H.: WO2006074546A1 (2006).
61. Maclachlan, I., Jeffs, L. B., Judge, A., Lee, A. C.: WO2006053430A1 ( 2006).
62. Chen, T., Vargeese. C., Vagle, K., Wang, W., Zhang, Y.: WO2007086883A2. (2007).
63. Jefferson, A. B., Zuckermann, R. N., Reinhard, C., Burkoth, T.: WO2005060697A2 (2005).
64. Monahan, S. D., Lewis, D. L., Herweijer, H., Wolff, J. A., Hagstrom, J. E., Loomis, A. G., Trubetskoy, V., Higgs, L.: US2005143332 (2005).
65. Vargeese, C., Wang, W., Chen, T., Sweedler, D., Haeberli, P.: WO2005007854A2 (2005).
66. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193(12): 1650-1657.
67. Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32(19): e149 doi:10.1093/nar/ gnh140.
68. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci 2005; 94(10): 2135-2146.
69. Kim SH, Mok H, Jeong JH, Kim SW, Park TG. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem 2006; 17(1): 241-244.
70. Kim EM, Jeong HJ, Park IK, et al. Asialoglycoprotein receptor targeted gene delivery using galactosylated polyethylenimine-graft-poly (ethylene glycol): in vitro and in vivo Studies. J Control Release 2005; 108(2-3): 557-567.
71. Oishi M, Nagasaki Y, Nishiyama N, et al. Enhanced Growth Inhibition of Hepatic Multicellular Tumor Spheroids by Lactosylated Poly(ethylene glycol)-siRNA Conjugate Formulated in PEGylated Polyplexes. ChemMedChem 2007; 2(9): 1290-1297.
72. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65(19): 8984-8992.
73. Triche, T. J. H., Siwen, I.: WO20070202076A1 (2007).
74. Pirollo KF, Rait A, Zhou Q, et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007; 67(7): 2938-2943.
75. Pirollo KF, Zon G, Rait A, et al. Tumor-targeting nanoimmuno-liposome complex for short interfering RNA delivery. Hum Gene Ther 2006; 17(1): 117-124.
76. Chang, E. H., Pirollo, K. F.: WO00050008A2 (2000).
77. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23(6): 709-717.
78. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007; 104(10): 4095-4100.
79. Lieberman, J., Song, E.: WO2006023491A2 (2006).
80. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448(7149): 39-43.
81. Farah MH. RNAi silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv 2007; 4(2): 161-167.
82. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249(4968): 505-510.
83. Hicke BJ, Marion C, Chang YF, et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 2001; 276(52): 48644-48654.
84. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002; 62(14): 4029-4033.
85. Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006; 103(32): 11838-11843.
86. Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev 2007; 107(9): 3715-3743.
87. Pestourie C, Tavitian B, Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005; 87(9-10): 921-930.
88. Barth, S., Wuellner, U., Neef, I.: WO2007071777A2 (2007).
89. Wullner U, Neef I, Eller A, et al. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets 2008; 8(7): 554-565.
90. McNamara JO, 2nd, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24 (8): 1005-1015.
91. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006; 34(10): e73.
92. Guo S, Tschammer N, Mohammed S, Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 2005; 16(9): 1097-1109.
93. Guo, P.: WO2007016507A2 (2007).
94. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel Dual Inhibitory Function Aptamer-siRNA Delivery System for HIV-1 Therapy. Mol Ther 2008; 16(8): 1481-1489.
95. Davis, M. E.: WO2006081546A2 (2006).
96. Epstein, D., Pendergrast, S., Keefe, A. D.: WO2005111238A2 (2005).